Genetic modification of preimplantation embryos: Toward adequate human research policies

Milbank Quarterly

Volumn 82, Issue 1, 2004, Pages 195-214

  Dresser, Rebecca ^a,b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF LAW   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA;

DNA MODIFICATION; EMBRYO; EXPERIMENT; FOOD AND DRUG ADMINISTRATION; GENE MUTATION; GENE TRANSFER; GENETIC ANALYSIS; GENOME ANALYSIS; GERM CELL; GOVERNMENT; HEALTH CARE ORGANIZATION; HEALTH CARE POLICY; HUMAN; HUMAN GENETICS; LAW; MEDICAL ETHICS; MEDICAL RESEARCH; POPULATION GENETIC PARAMETERS; PREGNANCY; PREIMPLANTATION EMBRYO; REVIEW; RISK ASSESSMENT; SCIENCE; STANDARDIZATION;

BIOMEDICAL AND BEHAVIORAL RESEARCH; GENETICS AND REPRODUCTION; LEGAL APPROACH;

BLASTOCYST; EMBRYO TRANSFER; GENETIC ENGINEERING; GENETICS, MEDICAL; HUMANS; RESEARCH; UNITED STATES;

EID: 1942439668     PISSN: 0887378X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.0887-378X.2004.00306.x     Document Type: Review

References (43)

1. Blaese, R.M. 2003. Germ Line Modification in Clinical Medicine: Is There a Case for Intentional or Unintended Germ Line Changes? In Designing Our Descendants: The Promise and Perils of Genetic Modification, edited by A.R. Chapman and M.S. Frankel, 68-76. Baltimore: Johns Hopkins University Press.
2. Botkin, J. 1998. Ethical Issues and Practical Problems in Preimplantation Genetic Diagnosis. Journal of Law, Medicine & Ethics 26:17-28.
3. Buchanan, A., D.W. Brock, N. Daniels, and D. Wikler. 2000. From Chance to Choice: Genetics and Justice. Cambridge, England: Cambridge University Press.
4. Capecchi, M. 2000. Human Germline Gene Therapy: How and Why. In Engineering the Human Germline, edited by G. Stock and J. Campbell, 31-42. New York: Oxford University Press.
5. Dresser, R. 2003. Human Cloning and the FDA. Hastings Center Report 33(3):7-8.
6. Federal Policy for the Protection of Human Subjects. 1991. Federal Register 56:28, 013-8.
7. Food and Drug Administration (FDA). 1984. Statement of Policy for Regulatory Biotechnology Products. Federal Register 49:50, 878-80.
8. Food and Drug Administration (FDA). 1993. Application of Current Statutory Authorities to Human Somatic Cell Therapy Products and Gene Therapy Products. Federal Register 58:53, 248-51.
9. Food and Drug Administration (FDA). 1998. Guidance for Industry: Guidance for Human Somatic Cell Therapy and Gene Therapy. Available at http://www.fda.gov/cber/gdlins/somgene.pdf (accessed June 10, 2003).
10. Food and Drug Administration (FDA). 2000. Human Gene Therapy and the Role of the Food and Drug Administration. Available at http://www.fda.gov/cber/ infosheets/genezn.htm (accessed June 6, 2003).
11. Food and Drug Administration (FDA). 2001. Additional Protections for Children in Clinical Investigations of FDA-Related Products. Federal Register 66:20, 589-600.
12. Food and Drug Administration (FDA). 2002. Meeting Documents, Biological Response Modifiers Advisory Committee (May 9-10). Available at http://www.fda.gov/ohrms/dockets/ac/cber02.htm (accessed July 18, 2003).
13. Food and Drug Administration (FDA). 2003a. IND Content and Format. Code of Federal Regulations 21:§312.23.
14. Food and Drug Administration (FDA). 2003b. Institutional Review Boards. Code of Federal Regulations 21:§56.
15. Food and Drug Administration (FDA). 2003c. Phases of an Investigation. Code of Federal Regulations 21:§312.21.
16. Frankel, M.S., and A.R. Chapman. 2000. Human Inheritable Genetic Modifications: Assessing Scientific, Ethical, Religious, and Policy Issues. American Association for the Advancement of Science Working Group. Available at http://www.aaas.org/spp/dspp/sfrl/germ line/main.htm (accessed April 24, 2003).
17. Frankel, M.S., and A.R. Chapman. 2001. Facing Inheritable Genetic Modification. Science 292:1303.
18. Friedmann, T. 2003. Approaches to Gene Transfer to the Mammalian Germ Line. In Designing Our Descendants: The Promise and Perils of Genetic Modification, edited by A.R. Chapman and M.S. Frankel, 39-54. Baltimore: Johns Hopkins University Press.
19. King, N. 2002. RAC Oversight of Gene Transfer Research: A Model Worth Extending? Journal of Law, Medicine & Ethics 30:381-9.
20. Kopelman, L. 2000. Moral Problems in Assessing Research Risk. IRB: Ethics and Human Research 22(5):3-6.
21. National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research. 1974. Research on the Fetus: Deliberations and Conclusions. Reprinted in Villanova Law Review 22(1976-77):300-14.
22. National Human Genome Research Institute. 2002. Workshop Summary (July 22). Available at http://www.genome.gov/10004761 (accessed July 17, 2003).
23. National Institutes of Health (NIH). 1994. Final Report of the Human Embryo Research Panel. Bethesda, Md.
24. National Institutes of Health (NIH). 2002. Points to Consider in the Design and Submission of Protocols for the Transfer of Recombinant DNA Molecules into the Genome of One or More Human Participants (April). In Guidelines for Research Involving DNA Molecules. Available at http://www4.od.nih.gov/oba/rac/ guidelines/ guidelines.html (accessed April 25, 2003).
25. Palmer, J.G., and R. Cook-Deegan. 2003. National Policies to Oversee Inheritable Genetic Modification Research. In Designing Our Descendants: The Promise and Perils of Genetic Modification, edited by A.R. Chapman and M.S. Frankel, 275-95. Baltimore: Johns Hopkins University Press.
26. Parens, E., and E. Juengst. 2001. Inadvertently Crossing the Germline. Science 292:397.
27. Recombinant DNA Advisory Committee. 2000. Prenatal Gene Transfer: Scientific, Medical and Ethical Issues. Available at http://www.4od.nih. gov/oba/rac/gtpcreport.pdf (accessed April 25, 2003).
28. Recombinant DNA Advisory Committee. 2002. Frequently Asked Questions: Recombinant DNA and Gene Transfer. Available at http://www.4od.nih.gov/oba/ RAC_FAQs.htm (accessed June 6, 2003).
29. Resnik, D.B. 2002. Bioethics of Gene Therapy. In Encyclopedia of Life Sciences, 166-73. London: Nature, Macmillan.
30. Resnik, D.B., H.B. Steinkraus, and P.J. Langer. 1999. Human Germline Gene Therapy: Scientific, Moral and Political Issues. Austin, Tex.: R.G. Landes.
31. Schultz, R.M., and C.J. Williams. 2002. The Science of ART. Science 296:2188-90.
32. Stock, G., and J. Campbell. 1998. Summary Report: Engineering the Human Germline Symposium. Available at http://research.mednet.ucla.edu/ pmts/germcont.htm (accessed April 24, 2003).
33. Stock, G., and J. Campbell. 2000a. Other Voices. In Engineering the Human Germline, edited by G. Stock and J. Campbell, 97-8. New York: Oxford University Press.
34. Stock, G., and J. Campbell. 2000b. The Road Ahead: A Panel Discussion. In Engineering the Human Germline, edited by G. Stock and J. Campbell, 73-95. New York: Oxford University Press.
35. Sutcliffe, A. 2002. Health Risks in Babies Born after Assisted Reproduction. BMJ 325:117-8.
36. U.S. Congress. 1996. Public Law 104-99:§128 (January 26).
37. U.S. Congress. 2003. Fetal Research. United States Code Annotated 42:§289g(b).
38. U.S. Department of Health, Education and Welfare (U.S. DHEW). 1979. Report of the Ethics Advisory Board. Federal Register 44:35, 033-58.
39. U.S. Department of Health and Human Services (U.S. DHHS). 2001. Additional Protections for Pregnant Women, Human Fetuses and Neonates Involved in Research. Federal Register 66:56, 778-80.
40. U.S. Department of Health and Human Services (U.S. DHHS). 2002a. Additional DHHS Protections for Children Involved as Subjects in Research. Code of Federal Regulations 45:§§46.401-9.
41. U.S. Department of Health and Human Services (U.S. DHHS). 2002b. Secretary's Advisory Committee on Human Research Protections Charter. Available at http://ohrp.osophs.dhhs.gov/ sachrp/charter.pdf (accessed July 16, 2003).
42. Walters, L., and J.G. Palmer. 1997. The Ethics of Human Gene Therapy. New York: Oxford University Press.
43. Willard, H.F. 2000. Artificial Chromosomes Coming to Life. Science 290:1308-9.